Last news analysis

New antibody drug helps patients breathe

by the editor with Reuters - 11 May 2021

The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.


Fosun Pharma to provide factory
with annual capacity of 1 bln doses
of BioNTech's COVID-19 vaccine

by the editor with Reuters - 10 May 2021

This marks a step closer for China to have localized manufacturing capability for the German firm's vaccine. Five domestically-developed COVID-19 vaccines are being used in the country, while no foreign ones have gained regulatory approval


U.S. backs giving poorer countries access to COVID-19 vaccine patents, reversing stance

by the editor with Reuters - 06 May 2021

President Joe Biden on Wednesday threw his support behind waiving intellectual property rights for COVID-19 vaccines, bowing to mounting pressure from Democratic lawmakers and more than 100 other countries, but angering pharmaceutical companies...


COVID vaccines: why waiving patents won't fix global shortage - scientist explains

by the editor with Reuters - 04 May 2021

COVID-19 vaccines are key to ending the pandemic. From a humanitarian, moral and pragmatic perspective, the countries must unite to ensure fair and rapid access to these vaccines, worldwide. As political and health leaders have stressed: no one is safe until we are all safe....


Next Covid-19 treatments:
what will they look like?

by the editor - 04 May 2021

According to the World Health Organization, there are 277 Covid-19 vaccines in devel-opment globally, of which 93 have entered human testing. Most of the projects in clini-cal testing are injected (78 projects representing 84 %). There are also two oral formu-lations (2 %) and seven nasal-spray formulations (8 %)...


Fareva Excella expands its high potent tablets
and capsules operations

by the editor - 03 May 2021

The global active pharmaceutical ingredients market is projected to reach USD 248.3 billion by 2025 from USD 187.3 billion in 2020, at a CAGR of 5.8% during the forecast period...


U.S. govt boosts Moderna COVID-19 vaccine contract to $1.25 bln

by the editor with Reuters - 29 April 2021

The U.S. government agreed to increase Moderna's COVID-19 vaccine contract from $ 236 million to approximately $ 1.25 billion, to include additional costs related to vaccine studies. ....


Nestle staff sought to help Lonza production
for Moderna vaccine: Swiss TV

by the editor with Reuters - 28 April 2021

Drugmaker Lonza Group, under pressure to find workers to help speed production of Moderna Inc's COVID-19 vaccine, is recruiting temporary employees from food giant Nestle to staff Swiss plants making ingredients for the shot....


Covid vaccines:
will the world face a surplus in capacity?

by the editor - 27 April 2021

Surges of new coronavirus infections blow up in various countries including India, Russia or even Japan. But Moderna's CEO, Stephane Bancel considers that the world may face a potential surplus next year in capacity...


How South Korea turbocharged specialty
syringe production for COVID-19 vaccines

by the editor with Reuters - 22 April 2021

It was 7:30 a.m. on Christmas Eve when Cha Jung-hoon, South Korea's deputy minister for small businesses, got a call from his boss to make an urgent three-hour car trip to visit syringe maker Poonglim Pharmatech...


Benefits Johnson&Johnson vaccine
outweigh the risks', EMA says

by the editor with Reuters - 21 April 2021

The European Medicines Agency (EMA) said on Tuesday (April 20) the benefits of inoculating the Johnson & Johnson's COVID-19 vaccine outweighed the risk of developing blood clots, after it found a link between the vaccine and rare occurrences of the side effect.


Q1 2021: a good pace for FDA and EMA's approvals

by the editor - 20 April 2021

In the first three months of 2021, 15 new drugs were approved by the FDA. This result beats the 12 approvals recorded last year and far exceeds the 7 approvals in Q1 2019. Nevertheless none of the most-anticipated drug approvals in 2021 occurred during the period.


Vaccines against Covid-19:
while they are now deployed around the globe,
who can be held liable in case of side effects?

by Cécile Théard-Jallu, Partners at the French law firm De Gaulle Fleurance & Associés
19 April 2021

While many countries are still fighting against the pandemic and struggling to fight vaccine doses to immunize their citizens, the harmlessness of some of the available vaccines, e.g. AstraZeneca and Janssen, is now more acutely debated due to side effects, more particularly thrombosis cases, having appeared, affecting certain segments of the population.


New consolidation announcement
in the CDMO and CRO markets

by the editor - 15 April 2021

Thermo Fisher Scientific Inc. is nearing a deal to buy pharmaceutical testing company PPD Inc. for more than $15 billion.


New steps on the road against Covid-19 pandemic

by the editor - 13 April 2021

With more than 133.9 million people around the world diagnosed with Covid-19 on April 8, and more than 2.9 million people dead, vaccination campaigns definitely are the main barrier against the pandemic. According to study findings published in the NEJM (New England Journal of Medicine), Moderna's vaccine mRNA-1273 appears to offer protection against Covid-19 for at least six months. Meanwhile, Pfizer and BioNTech's, BNT162b2, is said to be 91.3% effective at preventing the disease.


What is thrombocytopenia,
the rare blood condition possibly linked to the AstraZeneca vaccine?

by the editor with Reuters - 07 April 2021

Follows reports over recent weeks of blood clots in a small number of people around the world who had received the AstraZeneca vaccine. Scientists have termed the condition "vaccine induced prothrombotic immune thrombocytopenia" (VIPIT). But what does this actually mean, how significant is the risk?


Vaccines production accelerates,
so do worldwide death tolls

by the editor with Reuters - 07 April 2021

Will worldwide Covid-19 deaths decrease one day? According to a Reuters tally, they are rising once again, especially in Brazil and India, crossing 3 million on April 6. As it took more than a year for the global coronavirus death toll to reach 2 million, the additional 1 million deaths occurred in about three months, in spite of vaccination efforts across the globe.


CureVac's heavy development partnerships

by the editor - 31 March 2021

A day full of news for the two german manufacturers of anti-covid vaccines. On March 30, the two companies involved in developing a messenger RNA vaccine against Covid-19 announced important milestones. BioNTech and partner Pfizer indicated it expected to expand manufacturing capacity to up to 2.5 billion doses by end of 2021, with signed orders for 1.4 billion doses of its vaccine to date for delivery in 2021. Meanwhile CureVac disclosed it was organizing the manufacturing production of its CVnCoV vaccine candidate.


Vaccines against Covid-19 and Liabilities

By Alison Choy Flannigan - 30 March 2021

After Japan, France and the EU, now the Australian view:
"Liability issues with COVID-19 and COVID-19 vaccines - who should be responsible for adverse events?"


Messenger RNA technology:
who is in the race?

By the Editor (with Reuters) - 25 March 2021

Moderna Inc, Pfizer and BioNtech are not the only companies to use messenger RNA (mRNA) in their vaccines projects. Several drug manufacturers are also working hard on this technology to develop treatments and vaccines for various diseases.


Where are the European-manufactured
vaccine doses going?

By the Editor - 23 March 2021

Last year, much of Europe's leaders watched with dismay as the UK and US governments struggled to deal with the pandemic. The roles quickly changed, with the UK now administering over 40 doses of vaccine per 100 people and the US over 34 doses per 100 people. Within two days, last week, the United States succeeded in vaccinating 6 million people! The European Union administered a first dose to 10.4% of the population only on March 19, 2021 and 4.5% of the population received two doses of the vaccine. ...


short-term emotion or structural reality?

By Bernard Pluta, President Development Services Recipharm - 16 March 2021

Collectively, we did not see it coming on such a scale. The Covid-19 pandemic has exposed weaknesses in global pharmaceutical supply chains— in particular the dependence on Active Pharmaceutical ingredients (APIs) outsourced to Asia — and governments have responded forcefully with production relocation initiatives. Is this really a structural change or simply a short-term emotion? ...


Covid-19 manufacturing: why agreements between Big Pharma speed up?

By the Editor - 09 March 2021

With vaccination now well underway in every part of the world, it becomes more and more obvious that vaccine hesitancy is slowing down, whereas the need of millions of jabs is increasing...


Covid-19: four vaccines at a glance

By the Editor - 03 March 2021

With the FDA's authorization, end of February, for the use of the Johnson & Johnson coronavirus vaccine in adults, the world scientific community now has four different vaccines at its disposal to fight the pandemic.


Mobilization of American drugstores
in the vaccination campaign

From our correspondent Washington: Luke Watson - 02 March 2021

Joe Biden has retained Donald Trump's idea: he relies in part on drugstore and supermarket chains to administer millions of covid-19 vaccinations to Americans


What sales for 2020 FDA approved medicines?

By The Editor - 25 February 2021

With 53 drugs approved by the FDA, 2020 was very dynamic in terms of new approvals in spite of the sanitary crisis and the economic lockdown. But in the end, which products have taken the lead and reached the most sales?


The good performance of CDMOs
on the stock markets.

By The Editor - 16 February 2021

The values of public CDMO shares continued to outperform in 2020, with growth for the best between 70 and over 90% (Lonza, West Pharma and Catalent).


2020 financial results at a glance

By The Editor - 12 February 2021

How did major companies manage their businesses in 2020, amid Covid-19 pandemic, economic lockdowns and above all, "ups and downs" in R&D to bring to the market vaccines candidates against the virus?
PHARMAnetwork reviews the Top 5 pharmaceutical companies' 2020 financial results and 2021 forecasts.


The race for vaccine production capacities

By The Editor - 9 February 2021

The global market demand for anti-Covid vaccines is much higher than the current production capacities of Western countries. This demand could last for several years depending on several factors such as the duration of the effectiveness of vaccine immunization, the arrival of new variants leading to new vaccination campaigns, etc.



2020 European approvals in good health

By The Editor - 13 January 2021

Year-to-date tally at the European Medicines Agency (EMA) suggests the trend for new drug approvals in 2020 hasn't suffered from the Covid-19 pandemic. At the end of the 11 Committee for Medicinal Products for Human Use (CHMP) meetings, some 96 new medicines were approved in Europe throughout the year.


2020 FDA approvals: close to a new record

By The Editor - 07 January 2021

As Commissioner Stephen Hahn will depart the FDA by January 20, when the Biden administration takes office, review of drug approvals in 2020 shows the Covid-19 pandemic did not slow the trend. According to the FDA, the Center for Drug Evaluation and Research approved 53 "first-of-their-kind medicines" for the US market....


Covid-19 R&D: what else besides vaccines?

By The Editor - 3 December 2020

While Pfizer/BioNTech's Covid-19 vaccine candidate gained emergency use authorization in the UK on December 2, making it the first in Europe to get the green light, what happened in the rest of the pharma-industry? Many things for sure, as all companies are not exclusively working on vaccines.


Tracking the vaccine race

By the editor - 29 January 2021

Multiple “winners” are likely to make it to market, and success will depend on a number of factors reflected in this tracker.


which companies are still in the lead ?

By The Editor - 26 January 2021

Times are hard for vaccines candidates to succeed. Merck & Co's decision to discontinue its V590 and V5921 projects following disappointing early efficacy data on two potential Covid-19 vaccines shows that all developments will not get to the market eventually...


Without european CDMOs' no vaccines!

By the editor - 12 January 2021

European CDMOs are becoming essential players in producing the hundreds of millions of doses of anti-Covid-19 vaccines.


Covid-19 Vaccines:
The Exceptional Logistics Challenge

By The Editor - 27 November 2020

Humanity is faced with an unprecedented vaccination effort in order to achieve collective immunity close to 70%, or 5.5 billion people worldwide! Over 10 billion doses will need to be produced over time! Either by optimizing at best, in sterile vials of 10 doses, this represents a billion vials to be filled, packaged, stored, and sent to the places where the vaccine doses are distributed.


The ApiJect Gigafactory

By the editor - 12 January 2021

Featuring the world's largest pharmaceutical fill-finish facility...


Building the European Health Union

By The Editor - 18 November 2020

The European Health Union is on track; mid-November European Commission president, Ursula von der Leyen offered a €5 billion budget dedicated to health over the next seven years...


Is it time for the return of gene therapy?

By The Editor - 10 December 2020

The R&D on Covid-19 vaccines and treatments is not the only goal of Big Pharma. Interest in gene therapy development remains very high, as evidenced by several recent deals and agreements.


The "ups and downs" of Alzheimer's R&D

By The Editor - 12 November 2020

Will aducanumab become one day the first medication approved for Alzheimer? What happened last week confirms if needed that the story has not been written yet and that the cycle failure is not over...


Top 10 blockbusters' resilience in 2020

By The Editor - 5 November 2020

Were the Top 10 best-selling pharmaceutical drugs in the world impacted by social distancing measures, delays in elective surgeries, prioritization of Covid-19 patients during the first nine months of 2020? As most drugmakers have just announced their third quarter results, it is clear that Big Pharma's resilience is a reality, while blockbusters still make their way...


ESMO 2020: virtual but wealthy

By The Editor - 30 September 2020

The annual meeting of the European Society of Medical Oncology (ESMO) took place virtually this year, due to the Covid-19 pandemic. New treatment options were presented, new results were unveiled that could accelerate future adoption of medicines.

From our correspondent Washington


Amazon attacks the US pharmacy market

23 November 2020

American pharmacies and drugstore chains have a formidable new competitor: Amazon. The giants of the sector, CVS, Walgreens and RiteAid, but also the pharmacies of large low-cost distribution, such as Walmart and Costco, have been expecting for months such an official announcement, likely to upset the market of 300 billion dollars from the sale of drugs in the United States....


The European pharmaceutical relocation

A possible harmonization of the business conditions
of manufacturing agreements ?

By Nathalie CAZEAU - Cazeau & Associés
October 2020

The Coronavirus epidemic has caused shortages which have highlighted several difficulties in the pharmaceutical sector. To avoid this happening again, one of these solutions could be to repatriate production. This solution, envisaged by certain actors for some years already, could now be implemented at last. But if it is to be effective, it will require precise identification of the legal issues involved.


Buyouts speed up among Big Pharma
in spite of Covid-19

By The Editor - 4 February 2021

February 3, Jazz Pharmaceuticals agreed to pen a deal worth up to $7.2 billion for cannabinoid GW Pharmaceuticals, whose epilepsy med Epidiolex could become a blockbuster in sales.


Industrial redeployment
in Softgel pharmaceutical forms

By The Editor - 25 January 2021

NextPharma, CDMO specializing in finished oral and topical dosage forms (including sterile ophthalmics), acquires the industrial sites of Ploermel (FR) and Edinburgh (UK) from Lonza...


a new and profitable arena with Alexion?

By The Editor - 15 December 2020

AstraZeneca's $39 billion acquisition of Alexion strengthens several assumptions: firstly, rare-disease segment is more and more becoming a key issue for big and small pharmaceutical companies; secondly mega-deals are not over (it is the largest deal in AstraZeneca's history). And thirdly, there is still future for the pharmaceutical industry outside Covid-19 R&D.


EQT IX announces a public offer
to the shareholders of Recipharm AB

By The Editor - 14 December 2020

EQT IX, through Roar BidCo AB, announced a public offering of SEK 220 in cash per share to the shareholders of Recipharm AB and SEK 1,427,010 per Recipharm convertible bond with a par value of 1 000,000 SEK.


FINANCIAL: News & Stock

Stock Exchange

NYSE-New York SE

SWX-Swiss SE
DATA: Weekly chart

Coronavirus pandemic

Updated to january 20, 2021
Johns Hopkins University's Center for Systems Science and Engineering (CSSE) has assembled one of the simplest ways to track the virus worldwide.

Go to Top